"Real-world" evaluation of


Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
01 2020
Historique:
received: 08 10 2018
revised: 18 07 2019
accepted: 22 07 2019
pubmed: 27 8 2019
medline: 28 4 2021
entrez: 27 8 2019
Statut: ppublish

Résumé

The role of This is a retrospective multicenter observational study including 265 consecutive men who underwent Median PSA level at the time of PET/CT was 4.19 ng/ml. The decision to perform PET/CT was made after multidisciplinary discussion in 29.8% of cases; most were prescribed by urologists (50.2% of cases). Three main indications were concerned: biochemical recurrence after local treatment (61.1%), initial staging (26.0%), or at the time of progression to castration-resistance (12.9%). Upon biochemical recurrence, Indications of

Identifiants

pubmed: 31447087
pii: S1078-1439(19)30294-7
doi: 10.1016/j.urolonc.2019.07.017
pii:
doi:

Substances chimiques

fluorocholine 6029HGL0QP
Choline N91BDP6H0X

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2.e1-2.e9

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Vincent Niziers (V)

Department 2 of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France.

Romain Boissier (R)

Aix-Marseille University, Marseille, France; Department of Urology & Renal Transplantation, La Conception University Hospital, Assistance Publique -Hôpitaux de Marseille, Marseille, France.

Delphine Borchiellini (D)

Department of Oncology, Antoine-Lacassagne Center, Nice, France.

Jean-Laurent Deville (JL)

Service d'Oncologie Médicale, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France.

Cédric Khoury (C)

Centre Saint Louis; Pierre Guillet, Hôpital Font-Pré, Toulon, France.

Matthieu Durand (M)

Service d'urologie, d'andrologie et de transplantation rénale, Université de Nice-Sophia-Antipolis, Hôpital Pasteur 2, Centre hospitalier universitaire de Nice, Nice, France; Laboratoire de génétique des tumeurs solides-Institute for Research on Cancer and Aging of Nice (IRCAN)-INSERM U1081-CNRS UMR 7284-Université de Nice-Sophia-Antipolis, Nice, France.

Harry Toledano (H)

Department of Surgical Urology, North Hospital, Assistance-Publique-Marseille, Marseille, France.

Thomas Albert (T)

Service d'Urologie, Hôpital Sainte Musse, Toulon, France.

Nicolas Branger (N)

Department 2 of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France.

Quentin Bandelier (Q)

Aix-Marseille University, Marseille, France.

Matthieu-John Ouvrier (MJ)

Nuclear Medicine Department, A. Lacassagne Cancer Center, Nice, France.

Sophie Gabriel (S)

Nuclear Medicine Department, North Hospital, Assistance Publique-Hôpitaux de Marseille, Marseille, France.

Benjamin Hoch (B)

Centre Azuréen de Cancérologie, Mougins, France.

Emmanuel Gross (E)

Service de Radiothérapie, Ramsay Générale de Santé, Hôpital Privé Clairval, Marseille, France.

Jochen Walz (J)

Department 2 of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France.

Isabelle Brenot-Rossi (I)

Nuclear Medicine Department, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France.

Géraldine Pignot (G)

Department 2 of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France. Electronic address: pignotg@ipc.unicancer.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH